Lori Anne Kunkel - 04 Dec 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
04 Dec 2025
Net transactions value
+$20,752
Form type
4
Filing time
05 Dec 2025, 17:47:34 UTC
Previous filing
19 May 2025
Next filing
09 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kunkel Lori Anne Director C/O ORIC PHARMACEUTICALS, INC., 240 EAST GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Christian Kuhlen, attorney-in-fact 05 Dec 2025 0001536368

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Options Exercise $20,752 +5,534 +8.1% $3.75 74,200 04 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Stock Option (right to buy) Options Exercise $0 -5,534 -100% $0.000000 0 04 Dec 2025 Common Stock 5,534 $3.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022.